Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04806035
Title Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc

non-Hodgkin lymphoma

chronic lymphocytic leukemia


TG-1801 + Ublituximab


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.